Currency In USD
| Previous Close | 2.51 |
| Open | 2.47 |
| Day High | 2.58 |
| Day Low | 2.45 |
| 52-Week High | 3.94 |
| 52-Week Low | 1.66 |
| Volume | 212,733.81 |
| Average Volume | 2.55M |
| Market Cap | 383.81M |
| PE | -3.33 |
| EPS | -0.75 |
| Moving Average 50 Days | 2.8 |
| Moving Average 200 Days | 2.66 |
| Change | -0.01 |
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
GlobeNewswire Inc.
Oct 09, 2025 3:01 PM GMT
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing com
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming Eu